Codexis Announces Pricing of Public Offering of Common Stock

Impact · against what's priced in

Codexis shares face immediate downward pressure due to the dilution caused by a 16.7 million share public offering. While the $23.1 million in net proceeds strengthens the balance sheet for R&D and working capital, the dilution typically outweighs the short-term liquidity benefit.

CDXS−0.30

No priced-in read yet

In context

The pricing of 16,666,667 shares at $1.50 creates immediate equity dilution for existing shareholders, despite the addition of $23.1 million in net proceeds for general corporate purposes.

Read from the article alone

• public offering▲500%
• pharmaceuticals
• CDXS
• biotechnology
• common stock
• equity financing
• working capital

Top 1 mover · tap to explore